CombiMatrix Executes $350K Promissory Note | GenomeWeb

NEW YORK (GenomeWeb) – CombiMatrix said recently in its Form 10-Q that it executed a secured promissory note for $350,000 bearing a 10 percent annual interest rate.

In its document filed with the US Securities and Exchange Commission, the company said that it executed the promissory note on May 20 with ACC Investment. The note is secured by certain laboratory equipment used in its microarray services business and will be payable over a 36-month period. As of June 30 the fair value of the note was about $312,000.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: SNP reference panel from the Haplotype Reference Consortium, and more.

Halloran Consulting's Laurie Halloran lists at Stat News the mistakes she sees startup companies make when pursuing a clinical trial.

MIT researchers are using bees to collect and visualize urban microbiome samples, Wired reports.

Reliance on Excel leads to errors in gene name lists, a new Genome Biology paper reports.